Moderna (NASDAQ:MRNA) Stock: Insider Stephen Hoge Sells 39,215 Shares

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 39,215 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $211.61, for a total transaction of $8,298,286.15. Following the sale, the president owned 1,311,095 shares of the company’s stock, valued at $277,440,812.95. This represents a 2.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

  • On Monday, November 16th, Stephen Hoge sold 39,160 shares of Moderna stock. The shares were sold at an average price of $219.66, for a total transaction of $8,601,885.60.
  • On Thursday, October 15th, Stephen Hoge sold 39,145 shares of Moderna stock. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40.
  • On Wednesday, October 14th, Stephen Hoge sold 39,224 shares of Moderna stock. The shares were sold at an average price of $213.48, for a total transaction of $8,373,539.52.
  • On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22.
  • On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The stock was sold at an average price of $146.07, for a total transaction of $5,883,845.67.

Moderna Stock Performance

MRNA traded down $10.01 on Wednesday, reaching $196.79. The company had a trading volume of 6,901,633 shares, compared to its average volume of 12,504,324. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $280.80. The stock has a market capitalization of $79.63 billion, a PE ratio of -27.72 and a beta of 1.16. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average price of $204.39 and a 200-day moving average price of $98.06.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The business’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.51) earnings per share. As a group, research analysts forecast that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Institutional Trading of Moderna

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRNA. Liontrust Investment Partners LLP acquired a new stake in shares of Moderna during the 3rd quarter worth about $781,000. Integrated Wealth Concepts LLC raised its position in shares of Moderna by 49.7% in the third quarter. Integrated Wealth Concepts LLC now owns 11,459 shares of the company’s stock valued at $2,207,000 after buying an additional 3,806 shares during the last quarter. Kentucky Retirement Systems lifted its stake in shares of Moderna by 1.3% during the third quarter. Kentucky Retirement Systems now owns 22,907 shares of the company’s stock valued at $4,411,000 after buying an additional 286 shares during the period. Groupama Asset Managment purchased a new position in shares of Moderna during the third quarter valued at approximately $284,000. Finally, Diversify Advisory Services LLC purchased a new position in shares of Moderna during the third quarter valued at approximately $929,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of a number of research analyst reports. Sanford C. Bernstein reissued a “market perform” rating on shares of Moderna in a research report on Friday, September 25th. The Goldman Sachs Group boosted their price objective on Moderna from $137.00 to $195.00 and gave the company a “neutral” rating in a research note on Monday, November 9th. TD Cowen reissued a “buy” rating on shares of Moderna in a report on Wednesday, October 21st. Berenberg Bank increased their price objective on Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a report on Friday, September 11th. Finally, Jefferies Financial Group restated a “hold” rating and set a $150.00 target price (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Six analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $120.25.

Read Our Latest Research Report on Moderna

Top Moderna Stories

Investors following MRNA have been watching these stories:

About Moderna

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Read More

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.